Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment.

Sparks, Jeffrey A; Tedeschi, Sara K

Sparks, Jeffrey A; Tedeschi, Sara K.

Sparks JA; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston 02115, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: jsparks@bwh.harvard.edu.
Tedeschi SK; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston 02115, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Lancet Respir Med ; 10(9): 813-815, 2022 09.

Article in English | MEDLINE | ID: covidwho-1907938

Subject(s)

COVID-19 Vaccines; COVID-19; COVID-19/prevention & control; Humans; Immunogenicity, Vaccine; Immunosuppressive Agents; Methotrexate/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Lancet Respir Med Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google